Cytokinetics Corp (CYTK): Growth-Adjusted P/E Ratio

Cytokinetics is developing unique formulas to combat heart failure, which will grant the company pricing power, and is currently finalizing the market launch of a drug for hypertrophic cardiomyopathy. The PEG ratio trend helps identify undervalued assets, while 0.00 shows the value of this parameter. Cytokinetics relies on robust scientific potential and large-scale R&D investments in muscle biology and neurology.

CYTK Cytokinetics, Incorporated Price/Earnings to Growth Multiple (07/04/2022 - 11/10/2026)

Metric breakdowns and analytics for Cytokinetics (CYTK)

- share price and consensus valuation forecast:

Price Performance Chart Cytokinetics Inc.|CYTK - Price Target Chart

- stock exchange capitalization data:

Market Capitalization Cytokinetics Inc|CYTK - Enterprise Value

- business book valuation details:

Net Asset Value per Share Cytokinetics|CYTK - Company Net Assets|Market Capitalization to Book Value Ratio cytokinetics.com|CYTK - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and multiples data:

CYTK - Net Income|Expected Net Profit Cytokinetics|CYTK - P/E Multiple|Projected Price to Earnings Cytokinetics Corp|CYTK - Price/Earnings to Growth Multiple|Company Value to EBITDA Cytokinetics Inc|CYTK - Operating profit before deduction of amortization|Earnings per share for the last four quarters Cytokinetics|CYTK - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months cytokinetics.com|CYTK - Earnings per share growth in current year|Earnings growth forecast for next year Cytokinetics

Fundamental company analysis:Cytokinetics Inc. CYTK

Cytokinetics experienced management effectively minimizes clinical trial risks, ensuring a confident path toward drug commercialization. The current PEG ratio at 0.00 compares the market value of earnings to their growth rate: a value below one signals a fundamental undervaluation of the asset, allowing the investor to filter out market noise and identify explosive growth potential through this PEG ratio.

Competitors of Cytokinetics